CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS,

or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN **OUR DATABASE!!!**

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption): Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126 URL: http://www.jmir.org/2011/4/e126/

doi: 10.2196/jmir.1923 PMID: 22209829

* Required

Your name *

First Last

Dr. Ayeesha Kamal

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

The Aga Khan University, Karachi, Pakistar

Your e-mail address *

abc@gmail.com

ayeesha.kamal@aku.edu

Title of your manuscript *

Provide the (draft) title of your manuscript.

Showing 5-minute movies via a smartphone application to educate stroke survivors and their caregivers in an LMIC country does not control risk factors but reduces mortality after stroke - Results of Movies4Stroke; A Randomized Controlled Trial.

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Movies4Stroke

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

V2.5, Release 2015-01-01

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

Accessibility *

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Acute Stroke Survivors and their Caregiver

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

1. Control of three major risk factors, bloo

Secondary/other outcomes

"as needed"

Other:

Are there any other outcomes the intervention is expected to affect?

1. Stroke related mortality among stroke survivors; 2. Twelve months stroke disability and neurological deficits among stroke survivors

	commended "Dose" * It do the instructions for users say on how often the app should be used?
0	Approximately Daily
•	Approximately Weekly
0	Approximately Monthly
0	Approximately Yearly

Approx. Percentage of Users (starters)	still using	the app	as
recommended after 3 months	*			

- unknown / not evaluated
- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other:

Overall, was the app/intervention effective? *
yes: all primary outcomes were significantly better in intervention group vs control
partly: SOME primary outcomes were significantly better in intervention group vs control
on statistically significant difference between control and intervention
o potentially harmful: control was significantly better than intervention in one or more outcomes
inconclusive: more research is needed
Other: Secondary outcome of mortality among stroke survivors was statistical
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
,
At which stage in your article preparation are you currently (at the time you fill in this form)
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments submitted to a journal and accepted, but not published yet

Journal * If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")
onot submitted yet / unclear where I will submit this
Journal of Medical Internet Research (JMIR)
JMIR mHealth and UHealth
JMIR Serious Games
JMIR Mental Health
JMIR Public Health
JMIR Formative Research
Other JMIR sister journal
Other:
Is this a full powered effectiveness trial or a pilot/feasibility trial? *
Pilot/feasibility
C Fully powered
Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
on ms number (yet) / not (yet) submitted to / published in JMIR
Other: ms # 12113

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title



1a) Does your paper address CONSORT item 1a? *

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

	yes
--	-----

_	
	0.1
()	Other
\ /	Other.

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 1a-i? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Showing 5-minute movies via a smartphone application to educate stroke survivors and their caregivers in an LMIC country does not increase adherence but reduces mortality after stroke - Results of Movies4Stroke; A Randomized Controlled Trial"

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

1 subitem not at essential all important

Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We provided a Stroke Helpline number to our study participants where they could call at any time of day (24x7) to register their query (except any emergency) to a fully trained health care professional who would revert back to them within 24 hours after consulting a stroke specialist. This helpline number was available for participants in both the groups.

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 subitem not at essential all important

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"to educate stroke survivors and their caregivers in an LMIC country"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions



NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	\bigcirc	\circ	\circ		essential

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The video-based education intervention group had health education delivered through short videos that focused on a skill relevant to stroke that was shown to the participants and their caregivers at the time of admission, before discharge, at follow-up at first and third month post discharge. The control group had standardized care including pre-discharge education and counseling according to defined protocols of the center"

1b-ii) Level of human involvement in the METHODS section of the **ABSTRACT**

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0		0	0	essential

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This information is not directly relevant to be addressed in the abstract section as part of the main findings, otherwise the abstract will be too lengthy. Our intervention was a smart phone application which was installed in the cell phones of the study participants by a trained research officer, simultaneously, the entire applicability and the usage of the app was also demonstrated by the same person. Moreover, the study participants were demonstrated on how to use the application at home without any difficulty.

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-toface assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A randomized controlled, outcome assessor blinded, parallel group, single center superiority trial in which participants (stroke survivor - caregiver dyads) with first ever stroke (both ischemic and hemorrhagic) were randomized within 48 hours of their stroke to either the video-based education intervention group or the control group"

"A stroke survivor was defined as any adult aged 18 years of age or older, having experienced first ever stroke (ischemic or hemorrhagic) within the past 6 weeks, with mild to moderate disability, moreover, stroke is clinically stable and the stroke survivor is returning to the community for chronic care. Caregiver was defined as an adult aged 18 years of age or older who is present 24 hours a day with the stroke survivor and provides the overall day-to-day care of the stroke survivor. All participants enrolled in this video education intervention group and control group were followed for 12 months post discharge for the assessment of outcomes in the outpatient stroke clinics"

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	\circ	\circ	\circ	0	O	essential

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Three hundred and ten stroke survivors and their caregiver dyads (participant dyads) were recruited over a duration of six months. We screened 400 participant dyads to assess eligibility, of these 50 were not eligible and 40 participant dyads refused to participate in the study. One hundred and fifty-five participant dyads were randomized in the intervention group and control group respectively"

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The Movies4Stroke trial failed to achieve its primary specified outcome. There was no significant difference in control of three stroke risk factors; blood pressure, glucose or cholesterol. However, secondary outcomes that directly related to survival skills of stroke survivors demonstrated the effectiveness of video based intervention on improving stroke related mortality and survival without disability"



2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as standalone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 subitem not at essential all important

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In a country of a population of 180 million, roughly only 23 centers exist to provide physical medicine or help with rehabilitation; most have not adopted a multidisciplinary approach towards patients and none have inpatient services. Currently, there are no organized home care survival programs for stroke survivors in Pakistan involving primary caretakers"

"Despite these challenges, there is potential to leverage mobile technology to improve stroke outcomes. Pakistan has widespread mobile connectivity, with a cellular density of 77%. These infrastructure enablers create distinct opportunities for mHealth. Our rationale was to leverage IT based mHealth to provide a solution and knowledge and direct skills to the survivor and caregiver where provision of chronic continuous care is rudimentary"

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	\circ	\circ	0	\circ	O	essential

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Despite these challenges, there is potential to leverage mobile technology to improve stroke outcomes. Pakistan has widespread mobile connectivity, with a cellular density of 77%. These infrastructure enablers create distinct opportunities for mHealth. Our rationale was to leverage IT based mHealth to provide a solution and knowledge and direct skills to the survivor and caregiver where provision of chronic continuous care is rudimentary"

"We rationalized that the absence of trained personnel in the health community could be mitigated by actually providing high quality repetitive training using audio visual aids which served as a checklist for competency and survival skills to the stroke and caregiver dyad"

2b) In INTRODUCTION: Specific objectives or hypotheses



Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In this study, we aim to evaluate the effectiveness and safety of a locally designed, 5 minute movies rolled out in order of relevance, thematically delivered three months long program to deliver post-stroke education to stroke survivor and caregiver dyads returning to the community. We rationalized that the absence of trained personnel in the health community could be mitigated by actually providing high quality repetitive training using audio visual aids which served as a checklist for competency and survival skills to the stroke and caregiver dyad"

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio



Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A randomized control, outcome assessor blinded, parallel group, single center superiority trial was conducted to assess the efficacy of mobile phone video-based IT intervention in controlling three major risk factors (blood pressure, blood glucose and cholesterol) among adult stroke survivors"

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons



Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable. No important changes as such were made to the trial methodology after it's commenced.

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable. There were minor bug fixes or glitches identified during the pilot testing phases of our intervention (alpha, beta and gamma) which were resolved without any major change in the content. However, there was no major glitches or bug fixing issues identified during this process.

4a) Eligibility criteria for participants

B

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Eligibility Criteria:

Inclusion Criteria

- o Adult men and women greater than or equal to 18 years of age
- o Resident of Karachi and planning to live in Karachi till the follow-up period
- o Able to understand Urdu (language of the videos) and the national language
- o Admitted with first ever stroke (ischemic or hemorrhagic)
- o Modified Rankin score of less than or equal to 4 (mild to moderate disability)
- o Having at least one vascular risk factor that requires medical intervention
- o Consenting to participate in the study and for follow up visits, both stroke survivor and caregiver
- o Have a designated caregiver at home who is responsible for appointments, followup, overall care, e.g., wife, daughters, daughter- in- law, husband, etc.
- o Stroke was medically stable and participant was likely to return to the community after the in hospital stay (thus actively treated strokes e.g. decompressive surgeries, carotid endarterectomy, in hospital sepsis, ventilator complications that essentially preclude return to the community settings were not offered this chronic care support study).

Exclusion Criteria:

- o Serious aphasia, visual hemi-neglect, short term memory loss in the stroke survivor precluding understanding, visualization or retention of the video material. o Serious aphasia, visual hemi-neglect, short term memory loss, dementia in the caregiver precluding understanding, visualization or retention of the video material. o latrogenic stroke, stroke due to non-atherosclerotic vascular disease and rare causes e.g. Carotid dissections, gunshot to neck, post coronary artery by-pass graft surgery
- o Stroke survivor/Care-giver dyad continued post stroke care in a nursing assisted, professional or hospital setting and do not return to the community after discharge o Serious concurrent medical illnesses, like cancer, renal failure, acute liver disease in past 6 months (that precludes use of statins), chronic liver disease, that exclude the use of stroke preventive medications, or require non standardized therapy o Any use of off-label, non-guideline medications, due to stroke survivors' unique comorbid(s), that interferes with medication compliance to antihypertensive, statins, antiplatelet and anti-diabetic agents"

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

subitem not at essential all important

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Have a designated caregiver at home who is responsible for appointments, followup, overall care and are smartphone literate, e.g., wife, daughters, daughter-in-law, husband, etc"

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

subitem not at essential all important

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Informed consent was taken from eligible participants who volunteered to be part of this study, after a thorough explanation was provided to them regarding its nature and the scheduled follow-up visits. A detailed face to face interview of stroke survivors and their caregivers was conducted to gather data on socio-demographic and medical history. A baseline clinical and functional assessment was done after which they were randomly assigned into the intervention or the control group"

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Informed consent was taken from eligible participants who volunteered to be part of this study, after a thorough explanation was provided to them regarding its nature and the scheduled follow-up visits. A detailed face to face interview of stroke survivors and their caregivers was conducted to gather data on socio-demographic and medical history. A baseline clinical and functional assessment was done after which they were randomly assigned into the intervention or the control group"

4b) Settings and locations where the data were collected



Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A purposive sample was selected from adult stroke survivors being admitted to Stroke Unit, Neurology Ward, Aga Khan University Hospital, Karachi after the assessment of the eligibility criteria and informed consent has been obtained"

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in webbased trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	\bigcirc	\circ		\circ	\circ	essential

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable. There were no online surveys/questionnaires used in our trial.

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention. (Not a required item - describe only if this may bias results)

	1	2	3	4	5	
subitem not at all important	0	\circ		\circ	\circ	essential

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable for our trial as such. We recruited all the participants from a single center (Aga Khan University Hospital) for this mHealth clinical trial and all the study participants were admitted to the same hospital with a diagnosis of acute stroke. Moreover, all the participants in the intervention group knew that this smart phone application is a property of AKUH.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	\circ	\circ	0	O	0	essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Movies4Stroke application was developed by biomedical and software engineers of Aga Khan Development Network eHealth Resource Center (AKDN eHRC) in collaboration with stroke specialists, rehabilitation and swallowing experts and epidemiologists"

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 5 subitem not at essential all important

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The intervention was first pilot tested on study team members' android cell phone. Any discrepancies and bugs were removed from the application. The intervention was then launched in the tablets, specially purchased for showing the movies to the stroke survivors and their caregivers in clinical ward settings. Memory chips were also purchased so that the Stroke Movie Application can be transferred in the participants' cell phone"

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

1 subitem not at essential all important

Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The intervention was first pilot tested on study team members' android cell phone. Any discrepancies and bugs were removed from the application".

The intervention did not undergo significant changes after it was pilot tested nor the content of the application were changed.

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

1 subitem not at essential all important

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A study officer who was not blinded to the intervention group took several measures to ensure compliance of the participants to the videos as mentioned in the protocol"

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

subitem not at essential all important

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There are two figures in the manuscript to address this point. Figure 1 (Movies4Stroke Collage) and Figure 2 (Study Flow)

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

1 subitem not at essential all important

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Figure 1: Movies4Stroke Collage" in the manuscript is addressing this point

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 subitem not at essential all important

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The intervention was then launched in the tablets, specially purchased for showing the movies to the stroke survivors and their caregivers in clinical ward settings. Memory chips were also purchased so that the Stroke Movie Application can be transferred in the participants' cell phone"

"In addition to the usual care, the intervention group at the time of admission received the introductory teaching session with installation of the application and the first set of 5 minute videos on various stroke related topics as described below"

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and - if computermediated communication is a component - whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In addition to the usual care, the intervention group at the time of admission received the introductory teaching session with installation of the application and the first set of 5 minute videos on various stroke related topics as described below. In the first session, different skills such as swallowing exercises, different rehabilitation exercises and naso-gastric tube feeding were taught to the care-givers. The second session was delivered at the time of discharge which included videos on emergency preparedness, such as cardiopulmonary resuscitation, seizures, heart attack, hypoglycemia, simultaneously having discussion and answering any queries the participants had, after watching each set of videos. The third session was delivered at first month follow-up post discharge and included videos on frequently used medications by stroke survivors, such as anticoagulants, anti-hypertensive and lipid-lowering drugs. Fourth session was delivered at third month follow-up post discharge and included videos on secondary stroke prevention (recurrent attack) – exercise, physical activity, recognition of depression, diet modification and accurate measurement of blood pressure and blood sugar levels"

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

As discussed in the manuscript, in total, four sessions of the intervention (Movies4Stroke) were delivered to the participant dyads (stroke survivors and their caregivers) during the progress of this study. One at the time of admission, one at discharge, one at first month and the last at three months after discharge to the participants in the intervention group.

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 - generalizability).

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ		\circ	essential

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The mobile based intervention (Movies4Stroke) was first administered to the stroke caregivers by trained research officers with the help of a tablet and the subsequent sessions were delivered through smart phones of the caregivers (mHealth application installed in the same) at the time of discharge and two followup visits by the same research officers. Any query with respect to the administration of the application was resolved by the trained research personnel at the time of viewing in collaboration with the technical team.

Details of all these mentioned in the protocol.

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 subitem not at essential all important

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants in the intervention group were sent twice weekly messages as a reminder to watch the movies at home. These messages were sent through an online programmed open access software entitled "Frontline" by a trained I.T professional"

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as standalone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 - generalizability.

5 subitem not at essential all important

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Secondly, in this study, in order to maintain long-term follow up, the control group also had access to a 24/7 helpline, and interaction with healthcare personnel who assisted and resolved gueries may have improved adherence in this group as well. The presence of a centralized helpline has shown to help address gueries and also help patients cope with difficult situations"

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed



Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The primary outcome was; Control of three major risk factors, blood pressure, blood sugar and lipids, measured via standardized methods in the central laboratory were ascertained at baseline, 6th and 12th month post-discharge. All the three risk factors were assessed as the proportion of participants achieving the control of blood pressure (<125/85 mmHg), blood sugar (HbA1C <7%) and blood cholesterol (LDL <100 mg/dl) respectively.

The secondary were; Stroke related mortality among stroke survivors was ascertained at 12th month post-discharge, Stroke disability and neurological deficits among stroke survivors was ascertained at baseline, 6th and 12th month postdischarge"

6a-i) Online guestionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	\circ	\circ		\circ	\circ	essential

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Not Applicable for this study

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 5 subitem not at essential all important

Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

The number of times a particular movie was seen in a home environment by the participant dyads was recorded in the application and is currently being analysed and will be reported in the subsequent manuscript related to this mHealth trial.

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

1 subitem not at essential all important

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

The feedback related to the application (Movies4Stroke) was obtained through feedback forms and informal interviews. They have been analysed and will be reported in the subsequent manuscript as part of secondary outcomes.

6b) Any changes to trial outcomes after the trial commenced, with reasons



Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable

7a) How sample size was determined



NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Sample size calculation has been explicitly stated in the protocol keeping in mind the anticipated attrition rate.

7b) When applicable, explanation of any interim analyses and stopping guidelines



Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable

8a) Method used to generate the random allocation sequence



NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Stroke survivors and their caregivers (dyad) were assigned to either the intervention group or the usual care group in a parallel fashion in a ratio of 1:1. A computer generated randomization list was used to randomize subjects to the control group or the intervention group. The randomization center was at a secure computer in the Clinical Trials Unit and the randomization list was generated by CTU staff not involved in recruitment, outcome ascertainment or any aspect of the study "

8b) Type of randomisation; details of any restriction (such as blocking and block size)



Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Block randomization technique with a fixed block size of ten was used"

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization list was centralized and thus not predictable. No one from the research team had any access to randomization list, randomization envelopes, block size or code. It was made sure that envelopes were sealed, opaque and it was impossible to view the sequence even if held against bright sunlight. Randomization list and opaque envelopes containing the randomization sequence were always kept inside the premises of Clinical Trials Unit (CTU) under lock and key"

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The randomization center was at a secure computer in the Clinical Trials Unit and the randomization list was generated by CTU staff not involved in recruitment, outcome ascertainment or any aspect of the study"

"A baseline clinical and functional assessment was done after which they were randomly assigned into the intervention or the control group by a trained research officer who was not blinded to the assignment of the intervention"

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

	1	2	3	4	5	
subitem not at all important	0	\circ	0	\circ		essential

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The outcome assessor was blinded and was unaware of the assignment group.

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

	1	2	3	4	5	
subitem not at all important	0	\circ	0		0	essential

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes the study participants knew that whether they were receiving Movies4Stroke or not because of the nature of the intervention.

11b) If relevant, description of the similarity of interventions



(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable

12a) Statistical methods used to compare groups for primary and secondary outcomes



NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Statistical plan of analysis mentioned explicitly in the protocol.

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

	1	2	3	4	5	
subitem not at all important	\circ	\circ	\circ	O	\circ	essential

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Statistical plan of analysis mentioned explicitly in the protocol.

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses



Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Statistical plan of analysis mentioned explicitly in the protocol.

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)



X26-i) Comment on ethics committee approval

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study was approved from Ethical Review Committee (ERC) of Aga Khan University, Karachi (ERC# 3238-Med-ERC-14)"

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A written informed consent, in both English and Urdu, was obtained from all the study participants at the time of recruitment. The confidentiality and privacy of the participants was maintained by de-identification of the subject information. Only research staff was authorized entry into the hospital system on the computers that were used for data storage. All source documents were maintained in locked files in locked room. Fingerprint encryption was added to all sensitive data e.g. mobile numbers, app logs and error logs etc. The staff provided to this level of data access was very limited"

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

	1	2	3	4	5	
subitem not at all important	0	\circ	0	\circ	0	essential

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Only research staff was authorized entry into the hospital system on the computers that were used for data storage. All source documents were maintained in locked files in locked room. Fingerprint encryption was added to all sensitive data e.g. mobile numbers, app logs and error logs etc "



13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Three hundred and ten stroke survivors and their caregiver dyads, therefore 620 individuals (participant dyads) were recruited over a duration of six months. Since this clinical trial had a fixed block design, one hundred and fifty-five participant dyads were randomized in the intervention group and control group respectively (310 in each group). We screened 400 participant dyads to assess eligibility, of these 50 were not eligible and 40 participant dyads refused to participate in the study (30% were excluded)"

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The reasons for exclusions were 25 had MRS > 4, 15 had travel plans, 10 were not Karachi residents The reasons for refusal were mainly; lack of ability to return for follow-up, and lack of personal interest of the stroke survivor or caregiver to participate in the study. We were able to complete information on 141 participant dyads in the intervention group and 137 in the control group at the end of one-year post-discharge follow-up. From the intervention group, eleven participant dyads were lost to follow-up at one year post-discharge and three stroke survivors died due to in hospital mortality (before being discharged) due to inpatient complications from the index stroke, as compared to fifteen participant dyads who were lost to follow-up and three died due to in hospital mortality in the control group. There was one protocol violation in the control group which was excluded from the final analysis"

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	0	\bigcirc	\circ	\circ		essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Figure 3 in the manuscript

14a) Dates defining the periods of recruitment and follow-up



Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This point has been addressed in the heading of participants timeline "After recruiting stroke survivors along with their primary caregivers from the Stroke unit at AKUH, the participant dyads were not expected for any additional visits for the study purpose other than the scheduled five follow-up visits at the stroke clinic. Our study started enrolling participants from January 19th, 2015 and last participant was recruited on May 15th, 2015. The last follow-up was completed on June 29th, 2016"

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

	1	2	3	4	5	
subitem not at all important	0	\circ		0	\circ	essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable

14b) Why the trial ended or was stopped (early)



Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable

15) A table showing baseline demographic and clinical characteristics for each group



NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Table 1 in the manuscript.

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	\circ		0	0	essential

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Table 1 in the manuscript.

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups



16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

1 subitem not at essential all important

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This concept (Intention To Treat principle) has been used to report results across all the tables within the manuscript.

Moreover, the concept of using multiple denominators with absolute numbers and percentages have also been reported across all the tables within the manuscript.

16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

subitem not at essential all important

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Tables 3 to 10 for reporting of primary analysis through Intention To Treat principle.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Tables 3 to 10 for reporting of primary and secondary outcomes.

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0		0	\circ	essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not Applicable.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended



Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Tables 3 to 10 for reporting of primary and secondary outcomes.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Please refer to Appendix 3

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ		\circ	essential

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This sub-group analysis has been done and will be reported in the subsequent manuscript of Movies4Stroke.

19) All important harms or unintended effects in each group



(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harm or unintended effects in each group reported during the progress of this trial.

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 subitem not at essential all important

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No event as such was reported during the progress of this trial.

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

subitem not at essential all important

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not assessed in this manuscript but will surely be reported in the subsequent manuscript.

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	\circ		essential

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Movies for stroke is a randomized controlled mHealth trial evaluating the effectiveness and safety of a phone-based intervention which showed thematically designed videos to assist the stroke survivor and caregiver dyad to get the knowledge, skills and confidence needed to improve post-stroke medication adherence, risk factor control, survival and functional outcomes. The rationale of this trial was to provide repetitive high-quality survival and training to stroke survivor and caregiver dyads returning to a low-middle income community where rehabilitation and chronic care systems are underdeveloped. The mode of videobased IT intervention along with competency and understanding checks and the ability to repeat and see a video was used to assist understanding in a literacy challenged population which, however, had access to a cell phone. None of the trial participants were excluded due to lack of cell phone. This mHealth trial failed to reach its primary outcome measure of control of hypertension, LDL cholesterol and HbA1C, however the pre-specified secondary variables of improved functional outcomes and reduced mortality were improved in the intervention group in this study with highly significant results on mortality due to stroke related complications"

22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research.

1 5 subitem not at essential all important

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Our results demonstrate the key importance of health theory in designing these complex health interventions for replicability and for informing further interventions. Interventions that target compliance must have repetitive reminders for nonintentional adherence and interventions that target knowledge and skills transfer must have the capacity to repeat and bolster confidence, as well as provide the user the opportunity to model themselves from the materials taught, despite lack of literacy skills to be safe. Complex interventions targeting these settings need to have a design theory in place to deliver both these aspects to be effective"

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses



20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

subitem not at essential all important

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The major limitation of our clinical trial is that it is a single center study, chosen because of the fact that this site provided a standard of care that is algorithmic and replicable, thus results generated can be attributed to the effect of intervention. In this study, we reported its efficacy, but the performance and potential effect size in different sites may be variable and may potentially be more effective, given the usual care standards in even more resource strapped comparative health systems for e.g. the government sector and thus external validity is limited. Furthermore, those with more severe stroke or better health access due to socio economic status are more likely to visit this health system and are more likely to volunteer to participate in an educational training intervention, thus limiting direct external validity. Another significant limitation is of contamination bias in an educational intervention. Care was taken to avoid contamination of the non-intervention group with the intervention. To ensure this, videos were shown in a separate room, and not at the bedside. Given the fact that families do share information, contamination was possible, however most stroke survivors were on different schedules for follow-up visits, rehabilitation times etc. and so we expected less contamination than in areas where a lot of time is spent together by families. Obviously, it is an inherent limitation of an educational intervention that blinding of participants isn't possible"

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ	0		essential

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The major limitation of our clinical trial is that it is a single center study, chosen because of the fact that this site provided a standard of care that is algorithmic and replicable, thus results generated can be attributed to the effect of intervention. In this study, we reported its efficacy, but the performance and potential effect size in different sites may be variable and may potentially be more effective, given the usual care standards in even more resource strapped comparative health systems for e.g. the government sector and thus external validity is limited. Furthermore, those with more severe stroke or better health access due to socio economic status are more likely to visit this health system and are more likely to volunteer to participate in an educational training intervention, thus limiting direct external validity. We would definitely include non-response analysis in futures studies to further identify characteristics of those most likely to adopt the intervention. "

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

	1	2	3	4	5	
subitem not at all important	0	\circ	0	\circ		essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"There were trained research officers to ensure compliance of the intervention group participants at each video delivery, moreover, constant SMS reminders were sent to the study participants in the intervention group (as a measure of reinforcement) to watch these thematic movies in a relaxed home environment and they were also reminded about their scheduled follow-up visits"

"This intervention in a study setting required human resources in terms of a study officer, and IT back up, development required human resource, deployment required at least three staff in a study setting. In order to predict feasibility, we need to further analyse cost effectiveness and realistic compliance in a clinical setting with the current patient volumes, this limits directly recommending applicability. This study has collected data on cost effectiveness which is under analysis at this time"

OTHER INFORMATION

23) Registration number and name of trial registry



Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Clinicaltrials.gov NCT02202330

24) Where the full trial protocol can be accessed, if available



Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

https://www.ncbi.nlm.nih.gov/pubmed/26818913

25) Sources of funding and other support (such as supply of drugs), role of funders



Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center, National Institute of Neurologic Disorders and Stroke (NIH) and University Research Council, Aga Khan University (funders of this project)"

X27) Conflicts of Interest (not a CONSORT item)



X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	0	\circ	\circ		\circ	essential

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The authors have no conflicts of interest to declare. The authors are distinct from the sponsors of the intervention"

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your
manuscript? *
yes, major changes

- yes, minor changes

What were the most important changes you made as a result of using this checklist?

Mainly in the Methods section, specifically the questions focusing on the intervention part. And the other important change or addition was made in the Generalisability (External Validity) of Trial findings.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

Approx. 8 to 9 hours

As a result of using this checklist, do you think your manuscript has
improved? *

	yes
--	-----

	nc
\smile	

			_			
(-)	Ot	h	\sim	r	•
/		Οl	ш	C	L	•

Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

yes
,

()	no

Other:

Any other comments or questions on CONSORT EHEALTH

An extremely important guide to improve clinical trials focusing on eHealth and it makes the manuscript more rigorous.

STOP - Save this form as PDF before you click submit



To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!



Click submit so we have your answers in our database!

SUBMIT

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service

Google Forms